Amarin Corp Plc (AMRN)

[Whalatane]

Prior Art on EPA for Migraine Relief

A 12-week randomized, single-blind clinical trial found that dietary supplementation with fish oil, which contains EPA, led to a reduction in the number of headaches per month in patients with chronic migraine. The authors suggest this beneficial effect could be due to decreased production of pro-inflammatory molecules like prostaglandins, leukotrienes, and cytokines.
A randomized controlled trial published in The BMJ in 2021 looked at 182 people with chronic migraines. Participants on diets high in EPA and DHA (1.5 grams total per day) from fish had 30-40% fewer headache days per month and headache hours per day compared to those on a control diet low in EPA/DHA.
Another study found that 2 months of supplementation with 1 gram of omega-3 fatty acids, which are primarily EPA, significantly decreased the frequency and duration of migraines, with patients reporting a 74% reduction in headache duration.
The mechanisms by which EPA may reduce migraines include its anti-inflammatory effects, modulation of pain-regulating oxylipins, inhibition of vasodilation, and reduction of nociceptive (pain) responses in the brain.
However, some earlier studies did not find a significant difference in migraine outcomes between omega-3 supplementation and placebo. Overall, the evidence suggests EPA from fish oil has promise as a migraine treatment, but more research is needed to confirm its efficacy.

Kiwi